Advertisement

Clinical Studies of Iron-Chelating Treatment in Malaria

  • Victor R. Gordeuk
  • Godfrey Biemba
  • Philip E. Thuma

Abstract

Clinical studies have demonstrated that iron chelation therapy has acitivity against human malaria. Desferoxamine B clears parasitemia and symptoms in patients with uncomplicated falciparum and vivax malaria as a single agent, but recrudescence is common. In combination with quinine, desferrioxamine B enhances parasite clearance and speeds recovery from deep coma in children with cerebral malaria. At least two mechanisms have been proposed for the clinical activity of desferrioxamine B: (i) the inhibition of parasite growth by the withholding of iron and (ii) the protection of central nervous system tissue from free radical-mediated damage. Numerous in vitro studies have supported the first mechanism: the withholding of iron by iron chelators suppressed plasmodial growth in erythrocytes and hepatocytes. Studies of transferrin saturation in children with cerebral malaria have been consistent with the second mechanism. Prolonged coma was associated with abnormally high transferrin saturations, and the addition of iron chelation to the therapeutic regimen appeared to hasten recovery of full consciousness specifically in the children with high transferrin saturations.

Keywords

Cerebral Malaria Iron Chelation Vivax Malaria Transferrin Saturation Deep Coma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gilles HM: Management of Severe and Complicated Malaria: A Practical Handbook. Geneva, World Health Organization, 1991.Google Scholar
  2. 2.
    World Health Organization: Malaria Control in Countries where Time-Limited Eradication is Impracticable at Present. Technical Report Series No. 537. Geneva, World Health Organization, 1974.Google Scholar
  3. 3.
    Clyde DF: Recent trends in the epidemiology and control of malaria. Epidemiol Rev 1987; 9: 219–243.PubMedGoogle Scholar
  4. 4.
    Bezkorovainy A: Biochemistry of Nonheme Iron. New York, Plenum, 1980.Google Scholar
  5. 5.
    Scheibei LW, Sherman IW: Metabolism and organellar function during various stages of the life cycle: Proteins, lipids, nucleic acids and vitamins; in Wernsdorfer W, McGregor I (eds): Malaria: Principles and Practice of Malariologa New York, Churchill Livingstone, 1988, pp 219–252.Google Scholar
  6. 6.
    Wrigglesworth JM, Baum H: The biochemical features of iron; in Jacobs A, Worwood M (eds): Iron in Biochemistry and Medicine II. San Diego, Academic, 1980, pp 29–86.Google Scholar
  7. 7.
    Scheibel LW: Plasmodial parasite biology: Carbohydrate metabolism and related organellar function during various stages of the life cycle; in Wernsdorfer W, McGregor I (eds): Malaria: Principles and Practice of Malariology. New York, Churchill Livingstone, 1988, pp 171–217.Google Scholar
  8. 8.
    Scheibel LW, Rodriguez S: Antimalarial activity of selected aromatic chelators v. localization of 59Fe in Plasmodium falciparumin the presence of oxines. Prog Clin Biol Res 1989;313:119–149.PubMedGoogle Scholar
  9. 9.
    Raventos-Suarez C, Pollack S, Nagel RL: Plasmodium falciparum: Inhibition of in vitro growth by deferoxamine. Am J Trop Med Hyg 1982; 31: 919–912.PubMedGoogle Scholar
  10. 10.
    Fritsch G, Sawatzki G, Treumer J, Jung A, Spira DT: Plasmodium falciparum: Inhibition in vitrowith lactoferrin, desferrithiocin, and desferricrocin. Exp Parasitol 1987;63:1–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Yinnon AM, Theanacho EN, Grady RW, Spira DT, Hershko C: Antimalarial effect of HBED and other phenolic and catecholic iron chelators. Blood 1989; 74:2166–2171.PubMedGoogle Scholar
  12. 12.
    Whitehead S, Peto TEA: Stage-dependent effect of deferoxamine on growth of Plasmodium falciparum in vitro. Blood 1990; 76: 1250–1255.PubMedGoogle Scholar
  13. 13.
    Fritsch G, Treumer J, Spira DT, Jung A: Suppression of mouse infections with deferoxamine B. Exp Parasitol 1985;60:171–174.PubMedCrossRefGoogle Scholar
  14. 14.
    Hershko C, Peto TEA: Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 1988;168:375–387.PubMedCrossRefGoogle Scholar
  15. 15.
    Pollack S, Rossan RN, Davidson DE, Escajadillo A: Deferoxamine suppresses Plasmodium falciparumin Aotusmonkeys. Proc Soc Exp Biol Med 1987;184:162–164.PubMedGoogle Scholar
  16. 16.
    Modell B, Berdoukas V: Desferrioxamine; in: The Clinical Approach to Thalassaemia. London, Grune and Stratton, 1984, pp 216–241.Google Scholar
  17. 17.
    Brittenham GM: Iron chelating agents; in: Current Therapy in Hematology Oncology 3. St. Louis, Mosby, 1987, pp 149–153.Google Scholar
  18. 18.
    Gordeuk VR, Thuma PE, Brittenham GM, Zulu S, Simwanza P, M’hango A, Fleisch G, Parry D: Iron chelation with deferoxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 1992; 79:308–312.PubMedGoogle Scholar
  19. 19.
    Gordeuk VR, Thuma PE, Brittenham GM, Biemba G, Zulu S, Simwanza G, Kaiense P, M’hango A, Parry D, Poltera AA, Aikawa M. Iron chelation as a chemotherapeutic stragegy for falciparum malaria. Am J Trop Med Hyg 1993;48:193–197.PubMedGoogle Scholar
  20. 20.
    Bunnag D, Poltera AA, Viravan C, Looareesuwan S, Harinasuta KT, Schindlery C: Plasmodicidal effect of desferrioxamine B in human vivax and falciparum malaria from Thailand. Acta Tropica 1992; 52:59–67.PubMedCrossRefGoogle Scholar
  21. 21.
    Summers M, Jacobs A, Tudway D, Perera P, Ricketts C. Studies in desferrioxamine and ferrioxamine in normal and iron-loaded subjects. Brit J Haematol 1979:42:547–555.CrossRefGoogle Scholar
  22. 22.
    Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH: Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869–873.PubMedCrossRefGoogle Scholar
  23. 23.
    Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JVC, Rowley D, Halliwell B, Cornish A, Hider RC: Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985;56:345–355.PubMedGoogle Scholar
  24. 24.
    Polson RJ, Jawed A, Bomford A, Berry H, Williams R: Treatment of rheumatoid arthritis with desferrioxamine: Relation between stores of iron before treatment and side effects. Br Med J 1985;291: 48.CrossRefGoogle Scholar
  25. 25.
    Porter JB, Huehns ER: The toxic effects of desferrioxamine. Balliere’s Clin Haematolo 1989;2:459–474.CrossRefGoogle Scholar
  26. 26.
    Gordeuk VR, Thuma PE, Brittenham GM, McLaren CE, Parry D, Backenstose A, Biemba G, Msiska R, Holmes L, McKinley E, Vargas L, Gilkeson R, Poltera AA: Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. New Engl J Med 1992; 327:1473–1477.PubMedCrossRefGoogle Scholar
  27. 27.
    Molyneux ME, Taylor TE, Wirima JJ, Borgstein A: Clinical features and prognostic indicators in children with paediatric cerebral malaria: A study of 131 Malawian comatose children. Q J Med 1989; 71:441–459.PubMedGoogle Scholar
  28. 28.
    Scott MD, Ranz A, Kuypers FA, Lubin BH, Meshnick SR: Parasite uptake of desferrioxamine: a prerequisite for antimalarial activity. Brit J Haematol 1990;75:598–602.CrossRefGoogle Scholar
  29. 29.
    Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI: The antimalarial action of Desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993;91:218–224.PubMedCrossRefGoogle Scholar
  30. 30.
    Atkinson CT, Bayne MT, Gordeuk VR, Brittenham GM, Aikawa M: Stage-specific ultrastructural effects of desferrioxamine on Plasmodium falciparumin vitro. Am J Trop Med Hyg 1991;45:593–601.PubMedGoogle Scholar
  31. 31.
    MacPherson GG, Warrell MJ, Looareesuwan S, Warrell DA: Human cerebral malaria: A quantitative ultrastructural analysis of parasitised erythrocyte sequestration. Am J Pathol 1985;119:385–401.PubMedGoogle Scholar
  32. 32.
    Aikawa M: Human cerebral malaria. Am J Trop Med Hyg 1988;39:3–10.PubMedGoogle Scholar
  33. 33.
    McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159–163.PubMedCrossRefGoogle Scholar
  34. 34.
    Henson PM, Johnson RB: Tissue injury in inflammation: Oxidants, proteinases, and cationic proteins. J Clin Invest 1987;79:669–674.PubMedCrossRefGoogle Scholar
  35. 35.
    Sadrzadeh SMH, Graf E, Panter SS, Hallaway PE, Eaton JW: Hemoglobin: A biologic Fenton reagent. J Biol Chem 1984;259:14354–14356.PubMedGoogle Scholar
  36. 36.
    Sadrzadeh SM, Anderson DK, Panter SS, Hallaway PE, Eaton JW: Hemoglobin potentiates central nervous system damage. J Clin Invest 1987;79:662–664.PubMedCrossRefGoogle Scholar
  37. 37.
    Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH: Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989; 61: 319–322.PubMedGoogle Scholar
  38. 38.
    Dinarello CA, Cannon JG, Mier JW, Bernheim HA, Lo Preste G, Lynn DL, Love RN, Webb AC, Auron PE, Reuben RC, Rich A, Wolff SM, Putney SD: Multiple biological activities of human recombinant interleukin 1. J Clin Invest 1986;77:1734–1739.PubMedCrossRefGoogle Scholar
  39. 39.
    Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharoen S, Charoenlarp P, Brittenham G, Pippard MJ, Finch CA: The effect of erythroid hyperplasia on iron balance. Blood 1988; 71:1124–1129.PubMedGoogle Scholar
  40. 40.
    Ward PA, Till GO, Kunkel R, Beauchamp C: Evidence for role of hydroxyl radical in complement and neutrophil-dependent injury. J Clin Invest 1983;72:369–371.CrossRefGoogle Scholar
  41. 41.
    Gordeuk VR, Thuma PE, McLaren CE, Biemba G, Zulu S, Poltera AA, Askin JE, Brittenham GM: Transferrin saturation and recovery from coma in cerebral malaria. Blood 1995;85:in press.Google Scholar
  42. 42.
    Ambrosio G, Zweier JL, Jacobus WE, Weisfeldt ML, Flaherty JT: Improvement of postischemic myocar¬dial function and metabolism induced by administration of deferoxamine at the time of reflow: The role of iron in the pathogenesis of reperfusion injury. Circulation 1987;76:906–915.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • Victor R. Gordeuk
    • 1
    • 4
  • Godfrey Biemba
    • 2
  • Philip E. Thuma
    • 3
  1. 1.Department of MedicineThe George Washington University Medical CenterUSA
  2. 2.Macha Mission HospitalChomaZambia
  3. 3.Department of PediatricsHershey Medical Center Penn State UniversityHersheyUSA
  4. 4.USA

Personalised recommendations